Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Surg Oncol
Asıl Yazarlar: Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., Ariyan, Charlotte E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7112166/
https://ncbi.nlm.nih.gov/pubmed/31848819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08099-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller